Ovarian cancer-derived exosomes may impair anti-tumor immunity by carrying FasL/Fas (166), and FasL on ascites-derived exosomes in patients with epithelial ovarian cancer, as well as TRAIL, affects the presence of membranous forms of related ligand and partially explains lymphocyte apoptosis (39). This evidence concerns the gene FASLG and ovarian carcinoma.